Search
SOLACI Congress
HomeCONGRESSInternational Congresses

International Congresses

View Category
Day 1

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke,...
solaci -
Learn More
Day 1

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to...
solaci -
Learn More
Day 1

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated...
solaci -
Learn More
Day 1

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor...
solaci -
Learn More
Day 1

ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient

The aim of the study was to show a reduction in LDL cholesterol with the use of...
solaci -
Learn More
Day 1

SOLID-TIMI 52: Darapladib to reduce new cardiovascular events after myocardial infarction

This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days...
solaci -
Learn More
Day 1

MORE-CRT: Cardiac resynchronization with quadrupole electrode reduces complications

In approximately 10% of patients for resynchronization therapy implantation of ventricular lead is not possible for anatomical...
solaci -
Learn More
Day 1

POPE-2: Colchicine to prevent pericardial effusion after cardiac surgery

The incidence of asymptomatic pericardial effusion after cardiac surgery is high. The aim of this study was...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy